Brief: Biocartis: New Immuno-Oncology Project With Bristol-Myers Squibb

Biocartis NV

05/03/2020 06:19

March 5 (Reuters) - BIOCARTIS GROUP NV  BCART.BR :
    * BIOCARTIS ANNOUNCES NEW IMMUNO-ONCOLOGY PROJECT WITH
BRISTOL-MYERS SQUIBB AIMED AT REGISTRATION OF IDYLLA™ MSI TEST
IN CHINA
    * BRISTOL-MYERS SQUIBB AND BIOCARTIS HAVE NOW AGREED TO ADD
A NEW
PROJECT UNDER THEIR COLLABORATION
    * NEW PROJECT PURSUES REGISTRATION OF IDYLLA™ MSI TEST AS A
CDX
TEST IN MCRC IN PEOPLE'S REPUBLIC OF CHINA
    * BIOCARTIS GROUP NV - BIOCARTIS' JV WONDFO-CARTIS WILL
COMMERCIALIZE IDYLLA MSI TEST IN CHINA UPON OBTAINING REGULATORY
APPROVAL

Source text for Eikon:  ID:nGNE5DMZpQ 
Further company coverage:  BCART.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))